Patents Assigned to BIOATLA, LLC
-
Publication number: 20190010220Abstract: This disclosure relates to a chimeric antigen receptor for binding with a tumor specific target antigen. The chimeric antigen receptor comprises at least one antigen specific targeting region evolved from a parent protein or a fragment thereof and having a decrease in activity in the assay at the normal physiological condition compared to the activity in the assay under the aberrant condition. A method for producing the chimeric antigen receptor is also provided.Type: ApplicationFiled: September 7, 2018Publication date: January 10, 2019Applicant: BioAtla, LLCInventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
-
Publication number: 20190010219Abstract: This disclosure relates to a chimeric antigen receptor for binding with a target antigen. The chimeric antigen receptor comprises at least one antigen specific targeting region including a multispecific bivalent monovalent antibody evolved from a wild-type antibody or a fragment thereof and having at least one of: (a) a decrease CAB-scFv Affinity ELISA in activity in the assay at the normal physiological condition compared to the wild-type antibody or the fragment thereof, and (b) an increase in activity in the assay under the aberrant condition compared to the wild-type antibody or the fragment thereof. A method for using the chimeric antigen receptor and cytotoxic cells for cancer treatment is also provided.Type: ApplicationFiled: February 24, 2016Publication date: January 10, 2019Applicant: BioAtla, LLCInventor: Jay M. Short
-
Publication number: 20180371452Abstract: The present disclosure provides methods of integrating therapeutic protein and antibody generation and/or selection, evolution and expression in a eukaryotic host for manufacturing in a single system. Therapeutic proteins, including antibodies, are generated, optimized and manufactured in the same eukaryotic host system. The disclosed system of Comprehensive Integrated Antibody Optimization (CIAO!™) allows for simultaneous evolution of protein performance and expression optimization.Type: ApplicationFiled: August 31, 2018Publication date: December 27, 2018Applicant: BioAtla, LLCInventor: Jay Milton Short
-
Publication number: 20180362576Abstract: The present invention is relevant to proteins and novel methods of protein evolution. The present invention further relates to methods of identifying and mapping mutant polypeptides formed from, or based upon, a template polypeptide.Type: ApplicationFiled: July 27, 2018Publication date: December 20, 2018Applicant: BIOATLA, LLCInventor: Jay M. Short
-
Publication number: 20180340021Abstract: This disclosure relates to a chimeric antigen receptor for binding with a target antigen. The chimeric antigen receptor comprises at least one antigen specific targeting region including a multispecific antibody evolved from a wild-type antibody or a fragment thereof and having at least one of: (a) a decrease in activity in the assay at the normal physiological condition compared to the wild-type antibody or the fragment thereof, and (b) an increase in activity in the assay under the aberrant condition compared to the wild-type antibody or the fragment thereof. A method for using the chimeric antigen receptor and cytotoxic cells for cancer treatment is also provided. A method for producing the chimeric antigen receptor is also provided.Type: ApplicationFiled: August 2, 2018Publication date: November 29, 2018Applicant: BioAtla, LLCInventor: Jay M. Short
-
Patent number: 10106576Abstract: The present invention is relevant to proteins and novel methods of protein evolution. The present invention further relates to methods of identifying and mapping mutant polypeptides formed from, or based upon, a template polypeptide.Type: GrantFiled: March 4, 2011Date of Patent: October 23, 2018Assignee: BIOATLA, LLCInventor: Jay M. Short
-
Patent number: 10106788Abstract: The present disclosure provides methods of integrating therapeutic protein and antibody generation and/or selection, evolution and expression in a eukaryotic host for manufacturing in a single system. Therapeutic proteins, including antibodies, are generated, optimized and manufactured in the same eukaryotic host system. The disclosed system of Comprehensive Integrated Antibody Optimization (CIAO!™) allows for simultaneous evolution of protein performance and expression optimization.Type: GrantFiled: November 17, 2011Date of Patent: October 23, 2018Assignee: BIOATLA, LLCInventor: Jay Milton Short
-
Publication number: 20180259536Abstract: The present invention is relevant to polypeptides and novel methods of polypeptide evolution. The present invention further relates to methods of identifying a cross-species mutant polypeptide from, or based upon, a template polypeptide.Type: ApplicationFiled: January 7, 2015Publication date: September 13, 2018Applicant: BIOATLA, LLCInventor: Jay M. Short
-
Publication number: 20180237543Abstract: The present invention is relevant to the generation of multi-specific antibodies, antibodies that are distinguished by their ability to bind to multiple antigens with specificity and with affinity. In particular, the present invention is related to bi-specific antibodies.Type: ApplicationFiled: March 23, 2018Publication date: August 23, 2018Applicant: BioAtla, LLCInventors: Gerhard Frey, Hwai Wen Chang, Jay M. Short
-
Patent number: 10047357Abstract: The present disclosure provides methods of integrating therapeutic protein and antibody generation and/or selection, evolution and expression in a eukaryotic host for manufacturing in a single system. Therapeutic proteins, including antibodies, are generated, optimized and manufactured in the same eukaryotic host system. The disclosed system of Comprehensive Integrated Antibody Optimization (CIAO!™) allows for simultaneous evolution of protein performance and expression optimization.Type: GrantFiled: September 9, 2014Date of Patent: August 14, 2018Assignee: BIOATLA, LLCInventor: Jay Milton Short
-
Publication number: 20180186863Abstract: The present invention relates to modified Fc regions of antibodies, and uses thereof, such as in antibodies that contain an Fc region of the present invention.Type: ApplicationFiled: March 2, 2018Publication date: July 5, 2018Applicant: BIOATLA, LLCInventors: GERHARD FREY, JAY M. SHORT, HWAI WEN CHANG
-
Patent number: 9994841Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.Type: GrantFiled: October 28, 2016Date of Patent: June 12, 2018Assignee: BIOATLA, LLCInventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
-
Patent number: 9982252Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.Type: GrantFiled: September 11, 2014Date of Patent: May 29, 2018Assignee: BIOATLA, LLCInventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
-
Patent number: 9969813Abstract: The present invention is relevant to the generation of multi-specific antibodies, antibodies that are distinguished by their ability to bind to multiple antigens with specificity and with affinity. In particular, the present invention is related to bi-specific antibodies.Type: GrantFiled: May 10, 2013Date of Patent: May 15, 2018Assignee: BIOATLA, LLCInventors: Gerhard Frey, Hwai Wen Chang, Jay M. Short
-
Publication number: 20180086843Abstract: Anti-CD22 antibodies, including isolated nucleic acids that encode at least one such anti-CD22 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: ApplicationFiled: December 11, 2017Publication date: March 29, 2018Applicant: BIOATLA, LLCInventors: Jay Short, Gerhard Frey, Hwai Wen Chang, William Boyle
-
Patent number: 9856323Abstract: Anti-CD22 antibodies, including isolated nucleic acids that encode at least one such anti-CD22 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: GrantFiled: April 26, 2013Date of Patent: January 2, 2018Assignee: BIOATLA, LLCInventors: Jay Short, Gerhard Frey, Hwai Wen Chang, William Boyle
-
Publication number: 20170369867Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.Type: ApplicationFiled: September 8, 2017Publication date: December 28, 2017Applicant: BioAtla, LLCInventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
-
Publication number: 20170260261Abstract: This disclosure relates to a chimeric antigen receptor for binding with a target antigen. The chimeric antigen receptor comprises at least one antigen specific targeting region evolved from a wild-type protein or a domain thereof and having at least one of: (a) a decrease in activity in the assay at the normal physiological condition compared to the antigen specific targeting region of the wild-type protein or a domain thereof, and (b) an increase in activity in the assay under the aberrant condition compared to the antigen specific targeting region of the wild-type protein or a domain thereof. A method for generating the chimeric antigen receptor and cytotoxic cells that express the chimeric antigen receptor are also provided.Type: ApplicationFiled: August 27, 2015Publication date: September 14, 2017Applicant: BioAtla, LLCInventor: Jay M. Short
-
Publication number: 20170247685Abstract: A method of preparing a conditionally active biologic protein by selecting a wild-type biologic protein, evolving the DNA which encodes the wild-type biologic protein using one or more evolutionary techniques to create mutant DNAs, expressing the mutant DNAs in a eukaryotic cell production host to obtain a mutant protein, subjecting the mutant protein and the wild-type protein to an assay under a normal physiological condition and to an assay under an aberrant condition, selecting a conditionally active mutant protein which exhibits at least one of: (a) a decrease in activity in the assay at the normal physiological condition compared to the wild-type protein, and (b) an increase in activity in the assay under the aberrant condition compared to the wild-type protein; and producing the conditionally active biologic protein in the same eukaryotic cell production host used in the expression step.Type: ApplicationFiled: September 3, 2015Publication date: August 31, 2017Applicant: BioAtla, LLCInventor: Jay M. Short
-
Publication number: 20170247473Abstract: The disclosure provides a method for generation of humanized full length antibodies in mammalian cells. A library of humanized variants is provided with high, validated human framework diversity without requiring back-mutations to retain original affinity. Synthetic CDR encoding fragment libraries derived from a template antibody are ligated to human framework region encoding fragments from a human framework pool limited only to germline sequences from a functionally expressed antibodies. The vector comprises a nucleic acid sequence encoding HC framework region 4. No CDR grafting or phage display is required.Type: ApplicationFiled: May 12, 2017Publication date: August 31, 2017Applicant: BioAtla, LLCInventor: Jay M. Short